Ryght AI, the clinical trials technology company behind breakthrough AI Site Twin technology, today announced the formation of its inaugural Scientific Advisory Board SAB. This distinguished board will guide the companys research initiatives and strategic direction as it transforms clinical trial site selection, qualification, and activation through dynamic digital replicas of research facilities globally.
The SAB comprises globally recognized experts in oncology, hematology, dermatology, artificial intelligence, healthcare technology, and digital transformation. These leaders will provide Ryght AI with deep scientific and clinical insights, foster collaborative research with sponsors, and ensure the companys platform roadmap aligns with real-world challenges in study feasibility, patient recruitment, and operational performance.
Driving Scientific Excellence with Global Impact